(Q73207851)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10573117%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10573117%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

2

A V Schally

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10573117%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

K Szepeshazi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10573117%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A Nagy

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10573117%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 August 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10573117%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10573117%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10573117%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10573117%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

267-276

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10573117%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1006267327007

2 November 2019

exact match

0 references

cites work

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Recent trends in U.S. breast cancer incidence, survival, and mortality rates

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Anthracyclines in the treatment of cancer. An overview

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

UICC/CRC conference on targeted cancer therapy. Royal Free Hospital School of Medicine, London, December 17-19, 1991

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Targeted approaches to cancer therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Targeted toxins as anticancer agents

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Animal models of breast cancer: their diversity and role in biomedical research

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Gonadotropin-Releasing Hormone (GnRH)-Binding Sites in Human Breast Cancer Cell Lines and Inhibitory Effects of GnRH Antagonists*

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Hormone-drug conjugates.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021

Importance of interphase nucleolar organizer regions in tumor pathology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006267327007

7 January 2021